Sanofi India Limited

NSEI:SANOFI Stock Report

Market Cap: ₹139.4b

Sanofi India Valuation

Is SANOFI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SANOFI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SANOFI (₹6054.05) is trading above our estimate of fair value (₹1763.26)

Significantly Below Fair Value: SANOFI is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SANOFI?

Key metric: As SANOFI is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SANOFI. This is calculated by dividing SANOFI's market cap by their current earnings.
What is SANOFI's PE Ratio?
PE Ratio26.3x
Earnings₹5.30b
Market Cap₹139.40b

Price to Earnings Ratio vs Peers

How does SANOFI's PE Ratio compare to its peers?

The above table shows the PE ratio for SANOFI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average41.7x
GLS Glenmark Life Sciences
30.3x23.4%₹128.1b
532482 Granules India
27.8x22.1%₹135.5b
STAR Strides Pharma Science
78.1x45.6%₹138.3b
530019 Jubilant Pharmova
30.5x5.5%₹180.7b
SANOFI Sanofi India
26.3x-2.6%₹139.4b

Price-To-Earnings vs Peers: SANOFI is good value based on its Price-To-Earnings Ratio (26.3x) compared to the peer average (41.7x).

Price to Earnings Ratio vs Industry

How does SANOFI's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.6xn/aUS$70.43m
524652 Ind-Swift
2xn/aUS$13.12m
No more companies available in this PE range
SANOFI 26.3xIndustry Avg. 31.7xNo. of Companies18PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: SANOFI is good value based on its Price-To-Earnings Ratio (26.3x) compared to the Indian Pharmaceuticals industry average (31.7x).

Price to Earnings Ratio vs Fair Ratio

What is SANOFI's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SANOFI PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio26.3x
Fair PE Ratio27.6x

Price-To-Earnings vs Fair Ratio: SANOFI is good value based on its Price-To-Earnings Ratio (26.3x) compared to the estimated Fair Price-To-Earnings Ratio (27.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SANOFI forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹6,054.05
₹8,112.75
+34.0%
9.4%₹9,345.00₹7,421.00n/a4
Nov ’25₹6,772.25
₹8,176.25
+20.7%
8.6%₹9,345.00₹7,560.00n/a4
Oct ’25₹7,110.50
₹8,176.25
+15.0%
8.6%₹9,345.00₹7,560.00n/a4
Sep ’25₹6,809.00
₹8,176.25
+20.1%
8.6%₹9,345.00₹7,560.00n/a4
Aug ’25₹6,593.90
₹8,501.00
+28.9%
10.7%₹9,800.00₹7,560.00n/a5
Jul ’25₹6,551.85
₹9,350.80
+42.7%
13.7%₹11,500.00₹7,984.00n/a5
Jun ’25₹8,627.30
₹9,842.40
+14.1%
11.4%₹11,500.00₹8,125.00n/a5
May ’25₹8,325.55
₹9,497.60
+14.1%
11.1%₹11,300.00₹8,125.00n/a5
Apr ’25₹8,108.95
₹9,497.60
+17.1%
11.1%₹11,300.00₹8,125.00n/a5
Mar ’25₹8,666.05
₹9,370.80
+8.1%
11.1%₹11,300.00₹8,125.00n/a5
Feb ’25₹8,788.10
₹8,611.80
-2.0%
6.6%₹9,175.00₹7,850.00n/a5
Jan ’25₹8,124.05
₹8,391.80
+3.3%
11.0%₹9,175.00₹6,750.00n/a5
Dec ’24₹8,218.75
₹8,391.80
+2.1%
11.0%₹9,175.00₹6,750.00n/a5
Nov ’24₹7,593.40
₹7,490.60
-1.4%
6.5%₹8,028.00₹6,750.00₹6,772.255
Oct ’24₹7,207.30
₹7,287.17
+1.1%
8.7%₹8,028.00₹6,270.00₹7,110.506
Sep ’24₹7,115.90
₹7,287.17
+2.4%
8.7%₹8,028.00₹6,270.00₹6,809.006
Aug ’24₹6,999.20
₹7,211.86
+3.0%
9.5%₹8,213.00₹6,270.00₹6,593.907
Jul ’24₹6,912.30
₹7,138.83
+3.3%
10.5%₹8,213.00₹6,270.00₹6,551.856
Jun ’24₹6,839.10
₹7,138.83
+4.4%
10.5%₹8,213.00₹6,270.00₹8,627.306
May ’24₹5,570.10
₹6,502.83
+16.7%
5.1%₹6,900.00₹5,900.00₹8,325.556
Apr ’24₹5,735.40
₹6,501.17
+13.4%
5.1%₹6,900.00₹5,900.00₹8,108.956
Mar ’24₹5,812.85
₹6,501.17
+11.8%
5.1%₹6,900.00₹5,900.00₹8,666.056
Feb ’24₹5,448.05
₹7,173.86
+31.7%
11.0%₹8,315.00₹6,170.00₹8,788.107
Jan ’24₹5,853.05
₹7,245.29
+23.8%
10.0%₹8,315.00₹6,320.00₹8,124.057
Dec ’23₹5,687.45
₹7,245.29
+27.4%
10.0%₹8,315.00₹6,320.00₹8,218.757
Nov ’23₹5,634.85
₹7,637.86
+35.5%
10.4%₹8,500.00₹6,320.00₹7,593.407

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Mercury Laboratories

₹1.1b

Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.

538964

₹928.00

7D

-1.7%

1Y

15.6%

Vivimed Labs

₹410.4m

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India.

VIVIMEDLAB

₹4.95

7D

0%

1Y

-45.9%

Colinz Laboratories

₹138.6m

Manufactures, markets, and trades in pharmaceutical formulations in India.

531210

₹55.02

7D

-8.8%

1Y

33.1%